Are purified or expanded cord blood-derived CD133+ cells better at improving cardiac function?

Area of Science:

• Regenerative Medicine
• Cardiovascular Biology
• Stem Cell Therapy

Background:

• Endothelial progenitor cells (EPCs) expressing CD133 are crucial for angiogenesis but are deficient in high-risk cardiovascular patients.
• Myocardial infarction (MI) leads to tissue damage that normal angiogenesis cannot repair.
• Human umbilical cord blood (HUCB)-derived EPCs offer a potential solution for impaired stem cell function in vulnerable populations.

Purpose of the Study:

• To purify and expand CD133+ cells from HUCB.
• To assess the efficacy of these cells in a rat model of MI.
• To evaluate their potential for cellular cardiomyoplasty.

Main Methods:

• CD133+ cells were isolated from HUCB using magnetic microbeads.
• Cells were expanded in vitro with growth factors and characterized for EPC and mature endothelial cell (EC) markers.
• The therapeutic effect was evaluated by intramyocardial injection into rats with induced MI.

Main Results:

• Purified CD133+ cells expressed EPC markers, while expanded cells showed mature EC markers and formed tubule-like structures.
• Expanded cells expressed VEGF mRNA and retained functional activity after 70-fold expansion over 60 days.
• Both purified and expanded CD133+ cells significantly improved left ventricular ejection fraction in the rat MI model.

Conclusions:

• CD133+ cells from HUCB can be effectively purified and expanded in vitro while maintaining biological activity.
• Both purified and expanded CD133+ cells demonstrate promising therapeutic potential for MI treatment via cellular cardiomyoplasty.
• Further pre-clinical studies are warranted to compare the clinical advantages of expanded versus purified CD133+ cells.